Developing and testing a novel self-guided digital therapeutic solution for preventing stammering in children: incorporating latest research on early detection and progress evaluation using real-world data

开发和测试一种新颖的自我引导数字治疗解决方案，用于预防儿童口吃：结合使用真实世界数据进行早期检测和进展评估的最新研究

• 批准号: 10072187
• 金额: $ 31万
• 依托单位: RESPIRA LTD
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10072187
• 关键词: Developing; testing; novel; self; guided

**Need**Stammering typically begins between the ages of 2 and 6, and becomes chronic in adolescence for 25% of affected children. It affects 8% of children globally and 2% of teenagers and adults. Early detection of stammering in young children is crucial for effective intervention and treatment. However, currently available tools for detecting stammering are designed for speech and language therapists (SLTs), and long waiting lists to access SLTs can worsen mental health challenges.**Project Opportunity**Respira, a UK SME, aims to develop in this project a new therapeutic solution for early detection and progress evaluation of stammering in children who stammer that parents, guardians and caregivers (PGCs) can use and interpret without SLT support.With the support of a previous Innovate UK grant, Respira built BeneTalk: a digital therapeutic solution to provide accessible, effective, and ongoing support for chronic stammering. This project aims to develop a new solution, by leveraging existing BeneTalk expertise/framework/capabilities, thus expanding Respira's market share.The diagnostic and evaluation tools developed in the project will allow also Respira to assess the effectiveness of this project by using real-world data for evidence generation.The project will have a transformative effect on Respira's technical and commercial impact, increasing its TAM, and on the UK economy in terms of taxes and employment.**State-of-the-Art**There are no digital therapeutic solutions available for PGCs of children who stammer (CWS). The current standard of care is face-to-face therapy sessions with SLTs, which are limited or expensive, and without support outside the clinic or post-therapy. This project will be compatible with both the Lidcombe Programme and Palin Parent-Child Interaction Therapy, which are standard treatment practices. This will increase the adoption of this project and achieve better therapy outcomes.**Wider Impact**The project will transform the lives of CWS and PGCs by democratising access to speech therapy: It will improve mental health by addressing anxiety, depression, and other mental health conditions that affect both.Developing and commercialising this project will provide a cost-effective solution to tackle inequality due to the "postcode" lottery affecting UK speech therapy pathways. This project will enable the delivery of speech therapy in the home and reduce the need to travel to face-to-face appointments and follow-ups, which is estimated to be 1500 times greener than the standard of care. Developing such a humanitarian business benefits the UK economy due to high-skill jobs created, taxes collected, and national branding.

**需要** 口吃通常在 2 至 6 岁之间开始，25% 的受影响儿童在青春期时会变成慢性病。它影响全球 8% 的儿童以及 2% 的青少年和成人。早期发现幼儿口吃对于有效干预和治疗至关重要。然而，目前用于检测口吃的工具是为言语和语言治疗师 (SLT) 设计的，而获得 SLT 的漫长等待名单可能会加剧心理健康挑战。**项目机会**英国中小企业 Respira 旨在在此项目中开发一种新的治疗解决方案，用于早期检测和评估口吃儿童的口吃进展，父母、监护人和看护者 (PGC) 可以在没有 SLT 支持的情况下使用和解释。在英国创新资助下，Respira 开发了 BeneTalk：一种数字治疗解决方案，为慢性口吃提供方便、有效和持续的支持。该项目旨在通过利用现有的 BeneTalk 专业知识/框架/能力来开发新的解决方案，从而扩大 Respira 的市场份额。该项目中开发的诊断和评估工具也将使 Respira 能够通过使用现实世界来评估该项目的有效性用于证据生成的数据。该项目将对 Respira 的技术和商业影响产生变革性影响，增加其 TAM，并在税收和就业方面对英国经济产生变革性影响。**最先进**没有数字化治疗方案适用于口吃儿童 (CWS) 的 PGC。目前的护理标准是使用 SLT 进行面对面治疗，这种治疗效果有限或昂贵，并且没有诊所外或治疗后的支持。该项目将与标准治疗实践利德科姆计划和佩林亲子互动疗法兼容。这将增加该项目的采用并实现更好的治疗效果。**更广泛的影响**该项目将通过使言语治疗的普及化来改变 CWS 和 PGC 的生活：它将通过解决焦虑、抑郁和其他问题来改善心理健康该项目的开发和商业化将为解决由于“邮政编码”彩票影响英国言语治疗途径而造成的不平等问题提供一种具有成本效益的解决方案。该项目将实现在家中提供言语治疗，并减少前往面对面预约和随访的需要，预计这比护理标准环保 1500 倍。由于创造高技能就业机会、征收税收和国家品牌，发展这样的人道主义业务有利于英国经济。